Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaphorin-3B
- Development stage
- Preclinical
- Lead developer
- R&D Systems
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
SEMA3B recombinant protein is a research-grade biologic representing the human Semaphorin-3B protein, a member of the class 3 semaphorin family. It is primarily produced and sold by life science reagent suppliers for laboratory use to study its roles in axonal guidance, angiogenesis, and tumor suppression. SEMA3B acts as a secreted signaling molecule that binds to neuropilin-1 (NRP1), neuropilin-2 (NRP2), and plexin-A receptors to mediate cellular responses, including the induction of apoptosis in various cancer types such as lung, breast, and prostate cancer. Recent research has also explored its potential as a biomarker and therapeutic candidate in inflammatory conditions like ulcerative colitis, where it has been investigated for its ability to modulate intestinal inflammation in preclinical models.
- Other names
- SEMA3B recombinant proteinSEMA-3B recombinant proteinSEMA 3B recombinant proteinrecombinant human SEMA3Brecombinant human Semaphorin-3B
02
Targets
PLXNA1 (Plexin-A1)NRP2 (Neuropilin-2)NRP1 (Neuropilin-1)
Beyond the preview
Go deeper on semaphorin-3B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaphorin-3B.